Coccidiosis is a disease caused by intracellular protozoan parasites of the genus Eimeria that affect the intestinal tract of poultry. However, strain resistance and drug residue in the carcass have drawn the attention of the productive sector. The nanotechnology can improve the biological effect of drugs, reducing of administered doses and toxic effects. Due to this, toltrazuril-load polymeric nanoparticles based on Eudragit^® S100 (NCt) or poly-ε-caprolactone (LNCt) were developed to prevent coccidiosis in broilers. Nanoformulations were produced and showed homogeneous particle diameter distribution in the nanometer range (z-average and D (4.3) < 200 nm), negative zeta potential (<−8.93 mV), drug content ~100%, and encapsulation efficiency >90%. Cell viability assays using avian fibroblasts showed that LNCt presented no relevant toxicity up to 72 h. LNCt was then prophylactically administrated to chicken followed by challenge with Eimeria oocysts. The evaluation of the small intestine and cecum showed that the treatment with LNCt (3.5 mg/kg/day) in drinking water reduced the lesion scores and oocysts excretion, similar to the reference medicine containing toltrazuril (Baycox^®, 7 mg/kg/day). The current study shows the potential protective use of nanoencapsulating anticoccidial drugs as a promising approach for the control of coccidiosis in poultry.

Glioblastoma (GB) is a histological and genetically heterogeneous brain tumor that is highly proliferative and vascularized. The prognosis is poor with currently available treatment. In this study, we evaluated the cytotoxicity and antiangiogenic activity of doxorubicin-loaded-chitosan-coated-arginylglycylaspartic acid-functionalized-poly(ε-caprolactone)-alpha bisabolol-LNC (AB-DOX-LNC-L-C-RGD). The nanoformulation was prepared by self-assembling followed by interfacial reactions, physicochemically characterized and evaluated in vitro against GB cell lines (U87MG and U138MG) and in vivo using the chicken chorioallantoic membrane assay (CAM). Spherical shape nanocapsules had a hydrodynamic mean diameter of 138 nm, zeta potential of +13.4 mV, doxorubicin encapsulation of 65%, and RGD conjugation of 92%. After 24 h of treatment (U87MG and U138MG), the median inhibition concentrations (IC₅₀) were 520 and 490 nmol L⁻¹ doxorubicin-equivalent concentrations, respectively. The treatment induced antiproliferative activity with S-phase cell-cycle arrest and apoptosis in the GB cells. Furthermore, after 48 h of exposure, evaluation of antiangiogenic activity (CAM) showed that the relative vessel growth following treatment with the nanocapsules was 5.4 times lower than that with the control treatment. The results support the therapeutic potential of the nanoformulation against GB and, thereby, pave the way for future preclinical studies.

Solar ultraviolet (UV) radiation is a major contributor to skin damage, making the regular use of broad-spectrum sunscreens essential for effective photoprotection. However, the long-term efficacy of sunscreen formulations is limited by the photoinstability of some organic UV filters, particularly avobenzone. Licuri oil (Syagrus coronata) is a naturally derived Brazilian palm oil that represents a promising alternative to medium-chain triglycerides (MCTs) as an oily core for polymeric nanocapsules. Therefore, this study aimed to develop Eudragit^® RS 100-based cationic nanocapsules using licuri oil for avobenzone encapsulation and to incorporate them into hyaluronic acid (HA) or xanthan gum (XG) hydrogels. The nanocapsules ranged from 125 to 158 nm, with a polydispersity index (PDI) of less than 0.2, positive zeta potential (+11 to +13 mV), and encapsulation efficiency above 98%. After 48 h of UVA exposure, the nanocapsule formulations retained 51% and 52% of their initial avobenzone content for the licuri oil- and MCT-based systems, respectively, compared with only 10% for free avobenzone, indicating a marked improvement in photostability following nanoencapsulation. Additionally, licuri oil nanocapsules exhibited increased antioxidant activity compared to MCT-based nanocapsules in both DPPH and ABTS assays. The nanocapsule suspensions were classified as non- to slightly irritating in the Hen’s Egg Test–Chorioallantoic Membrane (HET-CAM) assay. After incorporation into the hydrogels, the resulting formulations exhibited pseudoplastic and thixotropic behavior, with HA-based hydrogels providing higher UV absorption than XG-based hydrogels. Furthermore, no transdermal permeation of avobenzone was observed from either the HA- or XG-based hydrogel formulations, and the HA hydrogel containing licuri oil nanocapsules showed higher stratum corneum retention. These findings demonstrate the potential of licuri oil as an effective alternative to MCTs as the oily core of polymeric nanocapsules for topical formulations containing encapsulated avobenzone.